FDA Approves First Drug for Serious Liver Disease

The FDA has approved Rezdiffra (resmetirom), the first drug for treating nonalcoholic steatohepatitis (NASH), a severe liver disease characterized by inflammation due to excessive fatty cells. NASH can lead to liver scarring and dysfunction over time, often associated with type 2 diabetes and high blood pressure.

Rezdiffra, a partial activator of the thyroid hormone receptor, aims to reduce liver fat accumulation. With an estimated 6-8 million affected individuals in the U.S., the approval marks a significant advancement, providing a treatment option beyond diet and exercise. Read more from The Hill here.